Detalhe da pesquisa
1.
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
Br J Haematol
; 189(5): 904-907, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32026474
2.
A novel method for the laboratory workup of anaphylactic transfusion reactions in haptoglobin-deficient patients.
Transfusion
; 60(4): 682-687, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31975382
3.
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 25(8): 1526-1535, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30831208
4.
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
Blood
; 130(20): 2196-2203, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28874350
5.
Comparison of Information-Dependent Acquisition on a Tandem Quadrupole TOF vs a Triple Quadrupole Linear Ion Trap Mass Spectrometer for Broad-Spectrum Drug Screening.
Clin Chem
; 62(1): 170-8, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26453698
6.
Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma.
J Appl Lab Med
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38573925
7.
Charge requirements for proton gradient-driven translocation of anthrax toxin.
J Biol Chem
; 286(26): 23189-99, 2011 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21507946
8.
The unfolding story of anthrax toxin translocation.
Mol Microbiol
; 80(3): 588-95, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21443527
9.
Lethal factor unfolding is the most force-dependent step of anthrax toxin translocation.
Proc Natl Acad Sci U S A
; 106(51): 21555-60, 2009 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-19926859
10.
Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster.
Blood Cancer J
; 12(8): 120, 2022 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35995768
11.
Immunotyping Provides Equivalent Results to Immunofixation in a Population with a High Prevalence of Monoclonal Gammopathies.
J Appl Lab Med
; 6(6): 1551-1560, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34329441
12.
Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.
J Appl Lab Med
; 6(6): 1476-1483, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34293131
13.
Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Pathology
; 53(3): 385-399, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33674146
14.
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Blood Rev
; 46: 100732, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32771227
15.
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
Clin Chim Acta
; 516: 136-141, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33545108
16.
Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers.
Environ Health Perspect
; 129(1): 17003, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33404262
17.
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Lancet Haematol
; 8(6): e422-e432, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34048681
18.
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
JAMA Oncol
; 7(6): 862-868, 2021 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33856405
19.
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Clin Cancer Res
; 27(19): 5195-5212, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34321279
20.
Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood.
Best Pract Res Clin Haematol
; 33(1): 101142, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32139008